OrbiMed Raises $3 Billion to Back Global Life Science Players
OrbiMed has raised $3 billion to back life science players worldwide, adding major dry powder to healthcare investing and widening the funding map for biotech and pharma firms globally.
Topic
Topic
OrbiMed has raised $3 billion to back life science players worldwide, adding major dry powder to healthcare investing and widening the funding map for biotech and pharma firms globally.
OrbiMed has secured $3 billion across its healthcare private equity funds, Vietnam Investment Review reports, in one of the secto…
OrbiMed has raised two new life sciences funds totaling $3 billion, BioSpace reports, with one vehicle targeting Asia's biotech a…
OrbiMed plans to invest $3 billion in healthcare opportunities across the US, Europe and Asia, FirstWord Pharma reports, a broad…
OrbiMed raised $3 billion across a global healthcare fund and an Asia-focused vehicle, per Pulse 2.0, giving the healthcare speci…
OrbiMed raised a $1.9 billion life sciences fund as part of a double close totaling roughly $3 billion, Dealroom reports — one of…
OrbiMed has raised $3 billion across two life sciences funds, Alternatives Watch reports, one of the larger sector-focused health…
OrbiMed closed its largest-ever Asian fund, bringing its new capital war chest to about $3 billion for healthcare and biotech dea…
OrbiMed closed $3 billion across separate U.S., European, and Asian healthcare investment funds in a single fundraising round, re…
OrbiMed Advisors has raised $3 billion for healthcare venture deals, one of the largest dedicated life-sciences pools, the Wall S…
OrbiMed Advisors has closed $3 billion across two healthcare venture funds, the Wall Street Journal reported, marking one of the…